See more : GUD Holdings Limited (GUD.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Shanghai Henlius Biotech, Inc. (2696.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shanghai Henlius Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Acusphere, Inc. (ACUS) Income Statement Analysis – Financial Results
- Deterra Royalties Limited (DRR.AX) Income Statement Analysis – Financial Results
- Southwest Securities International Securities Limited (0812.HK) Income Statement Analysis – Financial Results
- Simulated Environment Concepts, Inc. (SMEV) Income Statement Analysis – Financial Results
- Agios Pharmaceuticals, Inc. (0HB0.L) Income Statement Analysis – Financial Results
Shanghai Henlius Biotech, Inc. (2696.HK)
About Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.39B | 3.21B | 1.68B | 587.59M | 90.93M | 7.42M | 33.91M |
| Cost of Revenue | 1.48B | 844.62M | 522.75M | 182.12M | 71.82M | 5.40M | 15.02M |
| Gross Profit | 3.92B | 2.37B | 1.16B | 405.47M | 19.11M | 2.02M | 18.89M |
| Gross Profit Ratio | 72.64% | 73.73% | 68.93% | 69.01% | 21.01% | 27.26% | 55.71% |
| Research & Development | 1.12B | 1.39B | 1.02B | 894.14M | 607.83M | 365.38M | 257.08M |
| General & Administrative | 383.84M | 354.04M | 280.61M | 192.64M | 174.83M | 39.20M | 14.15M |
| Selling & Marketing | 1.75B | 1.05B | 520.26M | 243.65M | 45.69M | 0.00 | 0.00 |
| SG&A | 2.14B | 1.40B | 800.87M | 436.29M | 220.52M | 39.20M | 14.15M |
| Other Expenses | 0.00 | -69.04M | -41.90M | -35.39M | -7.45M | 64.00K | -410.00K |
| Operating Expenses | 3.29B | 2.73B | 1.78B | 1.30B | 820.90M | 458.55M | 343.85M |
| Cost & Expenses | 4.76B | 3.57B | 2.31B | 1.48B | 892.72M | 463.94M | 358.87M |
| Interest Income | 8.15M | 3.57M | 2.69M | 7.40M | 16.06M | 5.21M | 531.00K |
| Interest Expense | 110.54M | 105.67M | 84.82M | 43.71M | 48.31M | 57.90M | 55.16M |
| Depreciation & Amortization | 279.63M | 277.60M | 200.18M | 135.78M | 82.50M | 42.97M | 26.58M |
| EBITDA | 911.33M | -310.61M | -671.74M | -814.06M | -744.00M | -399.36M | -298.25M |
| EBITDA Ratio | 16.89% | -9.61% | -39.92% | -138.55% | -812.40% | -5,381.43% | -879.55% |
| Operating Income | 631.70M | -586.58M | -871.75M | -949.85M | -821.20M | -456.52M | -324.96M |
| Operating Income Ratio | 11.71% | -18.25% | -51.81% | -161.65% | -903.13% | -6,151.77% | -958.30% |
| Total Other Income/Expenses | -62.13M | -65.36M | -291.49M | -68.59M | -65.57M | -43.70M | -55.04M |
| Income Before Tax | 569.58M | -693.89M | -956.74M | -993.54M | -874.81M | -500.22M | -380.00M |
| Income Before Tax Ratio | 10.56% | -21.58% | -56.87% | -169.09% | -962.08% | -6,740.60% | -1,120.60% |
| Income Tax Expense | 23.56M | 1.37M | 27.31M | 43.69M | 655.00K | 4.57M | 4.33M |
| Net Income | 546.02M | -695.26M | -984.05M | -1.04B | -875.47M | -493.69M | -270.56M |
| Net Income Ratio | 10.12% | -21.63% | -58.49% | -176.52% | -962.80% | -6,652.55% | -797.88% |
| EPS | 1.00 | -1.28 | -1.83 | -1.96 | -1.76 | -0.95 | -0.50 |
| EPS Diluted | 1.00 | -1.28 | -1.83 | -1.96 | -1.76 | -0.92 | -0.50 |
| Weighted Avg Shares Out | 546.02M | 542.02M | 537.73M | 528.48M | 497.16M | 520.74M | 539.13M |
| Weighted Avg Shares Out (Dil) | 543.37M | 542.02M | 538.84M | 529.57M | 497.16M | 539.13M | 539.13M |
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Source: https://incomestatements.info
Category: Stock Reports